Zydus Cadila is currently trading at Rs. 368.95, up by 2.35 points or 0.64% from its previous closing of Rs. 366.60 on the BSE.
The scrip opened at Rs. 368.00 and has touched a high and low of Rs. 370.60 and Rs. 365.45 respectively. So far 22119 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 384.70 on 20-Jul-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 384.70 and Rs. 361.60 respectively. The current market cap of the company is Rs. 37893.83 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.78% respectively.
Zydus Cadila has received approval from US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in Chemotherapy Induced Anemia (CIA). Desidustat is expected to increase the red blood cell count and restore the erythropoietin levels to the normal levels in the cancer patients with CIA. Estimates suggest approximately 1.3 million cancer patients undergo chemotherapy every year in the United States and 30% to 90% of cancer patients receiving chemotherapy develop anemia.
Desidustat is a novel, oral, hypoxia inducible factor prolyl hydroxylase inhibitor, currently undergoing Phase 3 trials for treating anemia in Chronic Kidney Disease Patients. Zydus had initiated two Phase III trials of Desidustat. Zydus has also initiated a Phase II (b) trial of Desidustat in Mexico for the management of patients with COVID-19.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1504.25 |
| Dr. Reddys Lab | 6263.70 |
| Cipla | 1406.25 |
| Zydus Lifesciences | 948.20 |
| Lupin | 1615.85 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
